source
- GSK launches three-year cost-cutting plan as new CEO targets R&D efficiencyGSK announced a three-year restructuring program designed to cut costs and sharpen focus on its advanced assets. The plan was presented by CEO Luke Miels, who has been in the role for just over si…
- FDA advisory panel debates allowing compounding pharmacies to produce seven peptidesThe FDA’s advisory committee spent two days reviewing whether compounding pharmacies should be permitted to manufacture a set of seven peptide products. The discussion involved both committee membe…